[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.5483/BMBRep.2015.48.10.268

Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines

Choi, Song Hee (Departments of Microbiology, College of Medicine, Hallym University)
Park, Byoung Kwon (Departments of Microbiology, College of Medicine, Hallym University)
Lee, Keun-Wook (Departments of Biomedical Science, College of Natural Science, Hallym University)
Chang, Jun (Graduate School of Pharmaceutical Sciences, Ewha Womans University)
Lee, Younghee (Department of Biochemistry, College of Natural Sciences, Chungbuk National University)
Kwon, Hyung-Joo (Departments of Microbiology, College of Medicine, Hallym University)

Publication Information

BMB Reports / v.48, no.10, 2015 , pp. 565-570 More about this Journal

Abstract

In several reports, the respiratory syncytial virus (RSV) was identified as an oncolytic virus in cancer cells (e.g., lung and prostate cancer). However, the effects of RSV in hepatocellular carcinoma (HCC) cells have not yet been investigated. Here, we observed the inhibitory effects of RSV infection in HCC cell-lines. Cell growth was significantly decreased by RSV infection in BNL-HCC, Hep3B, Huh-7 and SNU-739 cells. After RSV infection, plaque formation and syncytial formation were observed in affected Hep3B and Huh-7 cells. RSV protein-expression was also detected in Hep3B and Huh-7 cells; however, only Huh-7 cells showed apoptosis after RSV infection. Furthermore, inhibition of cell migration by RSV infection was observed in BNL-HCC, Hep3B, Huh-7 and SNU-739 cells. Therefore, further investigation is required to clarify the molecular mechanism of RSV-mediated inhibition of HCC cell growth, and to develop potential RSV oncolytic viro-therapeutics.

Keywords

Apoptosis; Cell growth; Hepatocellular carcinoma; Oncolytic effect; RSV;

Citations & Related Records

Times Cited By KSCI : 6 (Citation Analysis)

Reference
Cited By KSCI

1	Stanford MM and McFadden G (2007) Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther 7, 1415-1425 DOI
2	Mohr I (2005) To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control. Oncogene 24, 7697-7709 DOI
3	Everts B and van der Poel HG (2005) Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 12, 141-161 DOI
4	Parato KA, Senger D, Forsyth PA and Bell JC (2005) Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5, 965-976 DOI
5	Kim HR, Heo YM, Jeong KI et al (2012) FGF-2 inhibits TNF-α mediated apoptosis through upregulation of Bcl2-A1 and Bcl-xL in ATDC5 cells. BMB Rep 45, 287-292 DOI
6	Youn JK, Kim DW, Kim ST et al (2014) PEP-1-HO-1 prevents MPTP-induced degeneration of dopaminergic neurons in a Parkinson’s disease mouse model. BMB Rep 47, 569-574 DOI
7	Kim S and Chang J (2012) Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease. Immune Netw 12, 8-17 DOI
8	Lee YD, Cui MN, Yoon HH, Kim HY, Oh IH and Lee JH (2014) Down-modulation of Bis reduces the invasive ability of glioma cells induced by TPA, through NF-kB mediated activation of MMP-9. BMB Rep 47, 262-267 DOI
9	Kim DS, Sohn EJ, Kim DW et al (2012) PEP-1-p18 prevents neuronal cell death by inhibiting oxidative stress and Bax expression. BMB Rep 45, 532-537 DOI
10	Heo J, Reid T, Ruo L et al (2013) Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19, 329-336 DOI
11	Chang J (2011) Current progress on development of respiratory syncytial virus vaccine. BMB Rep 44, 232-237 DOI
12	Atreya PL and Kulkarni S (1999) Respiratory syncytial virus strain A2 is resistant to the antiviral effects of type I interferons and human MxA. Virology 261, 227-241 DOI
13	Echchgadda I, Chang TH, Sabbah A et al (2011) Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense. BMC Cancer 11, 43 DOI
14	Tregoning JS and Schwarze J (2010) Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 23, 74-98 DOI
15	Falsey AR and Walsh EE (2000) Respiratory syncytial virus infection in adults.Clin Microbiol Rev 13, 371-384 DOI
16	Echchgadda I, Kota S, DeLa Cruz I et al (2009) Anticancer oncolytic activity of respiratory syncytial virus. Cancer Gene Ther 16, 923-935 DOI
17	Salimi V, Tavakoli-Yaraki M, Mahmoodi M et al (2013) The Oncolytic Effect of Respiratory Syncytial Virus (RSV) in Human Skin Cancer Cell Line, A431. Iran Red Crescent Med J 15, 62-67 DOI
18	Kelly E and Russell SJ (2007) History of Oncolytic Viruses: Genesis to Genetic Engineering. Mol Ther 15, 651-659 DOI
19	Kirn D, Martuza RL, Zwiebel J (2001) Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7, 781-787 DOI
20	Bell JC (2007) Oncolytic viruses: what's next? Curr Cancer Drug Targets 7, 127-131 DOI
21	Douek M and Taylor I (2003) Good practice and quality assurance in surgical oncology. Lancet Oncol 4, 626-630 DOI
22	Llovet JM, Burroughs A and Bruix J (2003) Hepatocellular carcinoma. Lancet 362, 1907-1917 DOI
23	Avila MA , Berasain C, Sangro B and Prieto J (2006) New therapies for hepatocellular carcinoma. Oncogene 25, 3866-3884 DOI
24	Kim JH, Oh JY, Park BH et al (2006) Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF. Mol Ther 14, 361-370 DOI
25	Woller N, Gürlevik E, Ureche CI, Schumacher A and Kühnel F (2014) Oncolytic viruses as anticancer vaccines. Front Oncol 4, 188 DOI
26	Russell SJ, Peng KW and Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30, 658-670 DOI
27	Liu TC, Hwang T, Park BH, Bell J and Kirn DH (2008) The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 16, 1637-1642 DOI
28	Heo J, Breitbach CJ, Moon A et al (2011) Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther 19, 1170-1179 DOI
29	Hoofnagle JH (2004) Hepatocellular carcinoma: summary and recommendations. Gastroenterology 127, S319-S323 DOI
30	Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45, 529-538 DOI
31	Parkin DM, Bray F, Ferlay J and Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108 DOI
32	Forver A, Llivet JM and Bruix (2012) Hepatocellular carcinoma. Lancet 379, 1245-1255 DOI
33	El-Serag HB and Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576 DOI

1	Seung-Ju Yang. (2017) Neurotoxicity Research N-Adamantyl-4-Methylthiazol-2-Amine Attenuates Glutamate-Induced Oxidative Stress and Inflammation in the Brain / 32 (1) , 107
6	Chang Hun Cho. (2016) Free Radical Research N-Adamantyl-4-methylthiazol-2-amine suppresses amyloid β-induced neuronal oxidative damage in cortical neurons / 50 (6) , 678
1	Hyo Sang Jo. (2017) Molecular Brain Tat-HSP22 inhibits oxidative stress-induced hippocampal neuronal cell death by regulation of the mitochondrial pathway / 10 (1)
11	Wern-Joo Sohn. (2016) BMB Reports Expression and characterization of transmembrane and coiled-coil domain family 3 / 49 (11) , 629
3	Eun-A Kim. (2017) Journal of Neuroimmune Pharmacology Neuroprotective Effect of 3-(Naphthalen-2-Yl(Propoxy)Methyl)Azetidine Hydrochloride on Brain Ischaemia/Reperfusion Injury / 12 (3) , 447
	Hyo Rim Ko. (2016) eLife Akt1-Inhibitor of DNA binding2 is essential for growth cone formation and axon growth and promotes central nervous system axon regeneration / 5
12	Jiae Kim. (2016) BMB Reports Protective effect of 3-(naphthalen-2-yl(propoxy)methyl)azetidine hydrochloride on hypoxia-induced toxicity by suppressing microglial activation in BV-2 cells / 49 (12) , 687
12	(2017) BMB Reports Gastrin-releasing peptide promotes the migration of vascular smooth muscle cells through upregulation of matrix metalloproteinase-2 and -9 / 50 (12) , 628
1	(2018) Scientific Reports Akt regulates neurite growth by phosphorylation-dependent inhibition of radixin proteasomal degradation / 8 (1)
6	(2017) BMB Reports Identifying the cellular location of brain cytoplasmic 200 RNA using an RNA-recognizing antibody / 50 (6) , 318